CXCL12-CXCR4-Mediated Chemotaxis Supports Accumulation of Mucosal-Associated Invariant T Cells Into the Liver of Patients With PBC

Zhilei Chen1,2, Suying Liu1,2, Chengmei He1,2, Jinlei Sun1,2, Li Wang1,2, Hua Chen1,2* and Fengchun Zhang1,2*

1 Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2 Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

Objectives: To explore the potential role of CD3+CD8+CD161high TCRα7.2+mucosal-associated invariant T (MAIT) cells in the pathogenesis of primary biliary cholangitis (PBC).

Methods: We enrolled 55 patients with PBC, 69 healthy controls (HCs), and 8 patients with hepatic hemangioma. Circulating MAIT cells and their chemokine receptor profiles and cytokine production were quantified using flow cytometry. Liver-resident MAIT cells were examined by immunofluorescence staining. CXCL12-mediated chemotaxis of MAIT cells was measured using a transwell migration assay. Plasma interleukin (IL)-18 was measured using ELISA, and cytokine production in IL-18-stimulated MAIT cells was detected using flow cytometry.

Result: Peripheral MAIT cells were found to be significantly lower in patients with PBC (3.0 ± 3.2% vs. 9.4 ± 8.0%, p < 0.01) and negatively correlated with alkaline phosphatase (ALP) levels (r = −0.3209, p < 0.05). Liver immunofluorescence staining suggested that MAIT cells might accumulate in PBC liver. MAIT cells from patients with PBC expressed higher levels of CXCR4 (84.8 ± 18.0% vs. 58.7 ± 11.4%, p < 0.01), and the expression of CXCL12 was higher in PBC liver. CXCL12 promoted MAIT cell chemotaxis (70.4 ± 6.8% vs. 52.2 ± 3.5%, p < 0.01), which was attenuated by CXCR4 antagonist. MAIT cells from PBC produced significantly more interferon-γ (IFN-γ) (88.3 ± 4.2% vs. 64.2 ± 10.1%, p < 0.01), tumor necrosis factor-α (TNF-α) (93.0 ± 1.1% vs. 80.1 ± 5.3%, p < 0.01), Granzyme B (89.3 ± 3.3% vs. 72.1 ± 7.0%, p < 0.01), and perforin (46.8 ± 6.6% vs. 34.8 ± 7.7%, p < 0.05). Plasma IL-18 was more abundant in patients with PBC (286.8 ± 75.7 pg/ml vs. 132.9 ± 78.1 pg/ml, p < 0.01). IL-18 promoted IFN-γ production in MAIT cells (74.9 ± 6.6% vs. 54.7 ± 6.7%, p < 0.01), which was partially attenuated by blocking IL-18R (68.6 ± 8.3% vs. 43.5 ± 4.2%, p < 0.01).
INTRODUCTION

Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by non-suppurative inflammation and immune-mediated destruction of small intrahepatic bile ducts, portal tract fibrosis, cirrhosis, and inflammation and immune-mediated destruction of small blood and tissues in the gut and the liver (1). PBC also presents systemic involvements beyond cholangitis, including interstitial lung disease, (2) pulmonary hypertension (3), and cardiomyopathy (4). The therapeutic approaches for PBC remain limited: ursodeoxycholic acid (UDCA) and ursodeoxycholic acid (Ocaliva) are the only FDA-approved agents, with ~60% biochemical response to UDCA (1, 5). Fibrates, methotrexate, colchicine, azathioprine, and liver transplant are unapproved alternatives (6, 7). Thus, investigation of the pathogenesis of PBC and potential therapeutic targets is urgently needed.

Mucosal-associated invariant T (MAIT) cells are a subset of unconventional T cells expressed as evolutionarily conserved invariant T-cell antigen receptors (TCRs), including semi-invariant α-chain Vα7.2-Jα33-20-12 in human and Vα19-Jα33 in mice (8). MAIT cells present in the peripheral blood and tissues in the gut and the liver (9, 10) actively produce interferon-γ (IFN-γ), interleukin (IL)-17, Granzyme B, and perforin in response to viral and bacterial challenges and show pro-inflammatory and cytotoxic phenotypes (11). Moreover, MAIT cells are implicated in liver diseases, including autoimmune liver disease and alcoholic or non-alcoholic hepatitis (12–14).

Mucosal-associated invariant T cells have been studied in PBC. Setsu et al. (15) report that MAIT cells are persistently activated and exhausted in patients with PBC and are lower in the peripheral blood and the liver. Jiang et al. (16) found reduced circulating MAIT cells but abundant liver-resident MAIT cells in patients with PBC, which is activated by IL-7 produced by cholic acid-stimulated hepatocytes. These studies have suggested that MAIT cells are potentially implicated in PBC. However, whether, and how, MAIT cells aggregate in the liver of patients with PBC remain unknown.

To address this issue, we analyzed the population and immunophenotype of peripheral MAIT cells from patients with PBC. We further analyzed the liver-resident MAIT cells in patients with PBC. Finally, we explored the underlying mechanism of liver accumulation and hyperactivation of MAIT cells from patients with PBC.

MATERIALS AND METHODS

Patients and Healthy Controls

We enrolled 55 patients with PBC who fulfilled the consensus criteria of PBC and were admitted to the Peking Union Medical College Hospital (PUMCH) from July 2017 to September 2019 (Table 1) (17). Substantial higher alkaline phosphatase (ALP), gamma-glutamyl transferase, and total bile acid were found in patients with PBC. We also enrolled 69 age- and sex-matched healthy volunteers as healthy controls (HCs). Additionally, eight patients with hepatic hemangioma who underwent surgical resection were enrolled as controls. This study was approved by the institutional review board of PUMCH. Written informed consent was obtained from all participants.

Flow Cytometry

Peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll gradient and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (Gibco, MD, USA) at 37°C. MAIT cells were stimulated with phorbol myristate acetate (PMA, 5 ng/ml) (Sigma-Aldrich, St. Louis, MO, USA), ionomycin (1 µg/ml) (Sigma-Aldrich, St. Louis, MO, USA), and brefeldin A (Biolegend, San Diego, CA, USA) for 2.5 h or anti-CD3 (5 µg/ml) (BD Biosciences, San Jose, USA) and anti-CD28 (5 µg/ml) (BD Biosciences, San Jose, USA) for 72 h. Intracellular staining was performed as previously described (18). Cell proliferation and apoptosis were detected using CFSE dilution (BD Biosciences, San Jose, CA, USA) and Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA). Data were acquired on a BD Aria II Cytometry (BD Biosciences, San Jose, CA, USA) and were analyzed using FlowJo software (Treestar, OR, USA).

Antibodies

Anti-CD3 (UCHT1), anti-CD8a (SK1), anti-TCRα7.2 (3C10), anti-CD161 (DX12), anti-CD69 (FN50), anti-CD38 (HIT2), anti-IL17A (BL168), anti-IFN-γ (4S.B3), anti-CXCR4 (12G5), anti-TNF-α (MAb11), anti-Granzyme B (GB11), anti-perforin (B-D48), anti-IL-18Rα (H44), anti-CCR5 (J148F1), anti-CCR6 (G034E3), anti-CCR10 (6588-5), anti-CX3CR1 (2A9-1), anti-CXCR1 (8F1/CXCR1), anti-CXCR3 (G025H7), anti-CXCR5 (J252D4), and anti-CXCR6 (K041E5) antibodies were purchased from BD Biosciences (San Jose, CA, USA) and BioLegend (San Diego, CA, USA).

Conclusion:

Mucosal-associated invariant T cells from patients with PBC accumulated in the liver via CXCL12-CXCR4-mediated chemotaxis, produced pro-inflammatory cytokines, and contributed to portal inflammation, which was potentially mediated by elevated IL-18. Targeting MAIT cells might be a therapeutic approach for PBC.

Keywords: primary biliary cholangitis, mucosal-associated invariant T cells, chemotaxis, CXCR4, CXCL12
TABLE 1 | Demographic and clinical characteristics of patients with PBC and healthy controls (HCs).

| Parameter | PBC (n = 55) | HCs (n = 69) | p-value |
|-----------|--------------|--------------|---------|
| Age—year | 52.55 ± 11.88 | 49.45 ± 8.88 | 0.10 |
| Female—sex | 55 (100%) | 69 (100%) | 1.00 |
| ALP—U/L | 112 (84–202) | 64 (56–79.5) | <0.001 |
| GGT—U/L | 53 (27–107) | 16 (13.5–27.5) | <0.001 |
| ALT—U/L | 31 (20–53) | 16 (12–19) | <0.001 |
| AST—U/L | 37 (25–47) | 18 (15–22) | <0.001 |
| TP—g/l | 76.73 ± 5.60 | 73.36 ± 4.35 | 0.03 |
| ALB—g/l | 42.09 ± 3.85 | 45.19 ± 3.03 | 0.35 |
| TBA—µmol/l | 6.20 (2.90–20.40) | 3.20 (1.95–5.25) | <0.001 |
| TBL—µmol/l | 13.51 ± 3.77 | 10.80 ± 4.78 | 0.18 |
| DBIL—µmol/l | 4.83 ± 2.08 | 3.84 ± 1.31 | 0.002 |
| TC—mmol/l | 5.05 ± 1.16 | 4.80 ± 0.93 | 0.49 |
| TG—mmol/l | 1.27 ± 0.72 | 1.42 ± 1.07 | 0.17 |
| HDL—mmol/l | 2.15 (1.47–3.23) | 1.28 (1.15–1.55) | <0.001 |
| LDL—mmol/l | 1.72 (1.39–2.81) | 2.6 (2.30–3.19) | <0.001 |
| Cr—µmol/l | 61.13 ± 13.09 | 61.04 ± 10.77 | 0.25 |
| BUN—µmol/l | 4.75 ± 1.30 | 4.45 ± 1.00 | <0.01 |
| UA—mmol/l | 295.8 ± 68.19 | 282.8 ± 74.66 | 0.40 |
| IgG—g/l | 15.42 (13.45–18.1) | NA | NA |
| IgA—g/l | 3.10 (2.37–4.24) | NA | NA |
| IgM—g/l | 2.40 (1.51–3.5) | NA | NA |
| ANA—% | 54 (3.98–19.1) | NA | NA |
| AMA—% | 91 (52.73) | NA | NA |
| Anti–GP210 (n = 15) | 8 (53.33%) | NA | NA |
| Anti–SP100 (n = 15) | 10 (66.67%) | NA | NA |

Values were presented as mean ± SD, median (interquartile range), or number (percentage). The data were analyzed using the Student’s t-test and Mann–Whitney U test.

CD8+ T cells from patients with PBC were starved in RPMI-1640 medium containing 1% FBS overnight. The cells were seeded in the upper transwell chamber (Corning, NY, USA), and media containing 0, 10, 30, or 50 ng/ml CXCL12 (Peprotech, NJ, USA) were added to the lower chamber for 1.5 h. Cells in both chambers were harvested and mixed with 123 count eBeads (Thermo Fisher Scientific, MA, USA); stained with fluorochrome-conjugated anti-CD3, anti-CD8a, anti-TCRα7.2, and anti-CD161 antibodies; and processed with a flow cytometer. Chemotaxis rate was calculated as the percentage of MAIT cells in the lower chamber of the total MAIT cells. For blocking CXCR4, the cells were pre-treated with AMD3100 (1 µg/ml) (TOCRIS, Abingdon, UK) for 30 min before loading onto the upper chamber.

**CYTOKINE MEASUREMENT**

IL-18 was measured using the IL-18/IL-18 BPa Complex DuoSet ELISA (R&D Systems, MN, USA) according to the instructions of the manufacturer. All tests were performed in duplicate.

**Immunohistochemistry and Immunofluorescence**

Liver tissues fixed with paraformaldehyde (PFA) were stained with anti-CXCL12 (R&D Systems, MN, USA) antibody. In brief, the tissue sections were deparaffinized, rehydrated, and treated with an EDTA buffer antigen retrieval solution for 26 min. After blocking endogenous peroxidase with 3% H2O2 and 3% BSA at room temperature for 30 min, slides were incubated with a mouse anti-CXCL12 antibody (R&D Systems, MN, USA) overnight at 4°C. The slides were washed and covered with HRP-conjugated anti-mouse antibodies (Servicebio, Wuhan, China) at room temperature for 50 min. The slides were developed with diaminobenzidine (DAB), counterstained in the nucleus with hematoxylin, washed, dehydrated in series-gradient ethanol, washed, and mounted on a microscope. The density of CXCL12+ cells (cells/mm²) was quantified using Image J [National Institutes of Health (NIH)].

**Chemotaxis Assay**

Peripheral blood mononuclear cells from patients with PBC were stimulated with plate-bound anti-CD3 (5 µg/ml), anti-CD28 (5 µg/ml), and IL-18 (100 ng/ml), (BioLegend, San Diego, CA, USA) at 37°C for 48 h. Cells were harvested, and the production of IFN-γ was measured using a flow cytometer. For blocking IL-18 R, the cells were pre-treated with anti-IL-18Rα/IL-1R5 (1 µg/ml) (R&D Systems, MN, USA) antibody for 30 min.

**IL-18 Stimulation Assay**

Peripheral blood mononuclear cells from patients with PBC were stimulated with plate-bound anti-CD3 (5 µg/ml), anti-CD28 (5 µg/ml), and IL-18 (100 ng/ml), (BioLegend, San Diego, CA, USA) at 37°C for 48 h. Cells were harvested, and the production of IFN-γ was measured using a flow cytometer. For blocking IL-18 R, the cells were pre-treated with anti-IL-18Rα/IL-1R5 (1 µg/ml) (R&D Systems, MN, USA) antibody for 30 min.

**Statistical Analysis**

The data were summarized as the mean ± SD, median (interquartile range), or number (percentage). For normal distribution data, the Student’s t-test was used to compare the differences between the two groups. A paired t-test was used to compare the differences between the paired samples at different conditions. Non-normal distribution data were analyzed using the Kolmogorov–Smirnov test, ANOVA, and the Mann–Whitney U test. Correlations were calculated using Spearman’s correlation analysis. A two-sided p < 0.05 was considered statistically significant. The data were analyzed using the SPSS V.17.0 software (IBM, NY, USA).
RESULTS

Lower Peripheral MAIT Cells From Patients With PBC

We first examined CD3+CD8+CD161high TCRVα7.2+ MAIT cells in PBMCs from patients with PBC and from HCs. We found that the frequencies of MAIT cells in CD3+CD8+T cells from patients with PBC were significantly lower than those from HCs (3.0 ± 3.2% vs. 9.4 ± 8.0%, p < 0.01, Figure 1A). Consistently, the number of circulating MAIT cells in PBMCs from patients with PBC was lower than those from HCs (1,186 ± 1,491 vs. 6,866 ± 6,154 cells per 10⁸ PBMCs, p < 0.01, Figure 1B). Furthermore, circulating MAIT cells from patients with PBC showed significantly higher levels of CXCR4 than those from HCs (84.8 ± 8.0% vs. 58.7 ± 11.4%, p < 0.01). Moreover, CXCR4 endogenous ligand CXCL12 was overexpressed in the liver of patients with PBC (Figure 2A). No significant correlation was observed between γ-glutamyltransferase (GGT), total bile acid (TBA), total bilirubin (TBIL), creatinine (Cr), γ-glutamyltransferase (GGT), alanine aminotransferase (ALT), total cholesterol (TC), total triglycerides (TG), uric acid (UA), and immunoglobulin G (Supplementary Figure 1). Collectively, MAIT cells decreased in the peripheral blood of patients with PBC and inversely correlated with the disease activity of PBC, suggesting that MAIT cells might play a role in the pathogenesis of PBC.

MAIT Cells From Patients With PBC Show a Higher Potential of Inflammation

We further investigated the immunophenotype of MAIT cells from patients with PBC. We found that the activation markers, CD69 (35.0 ± 32.0% vs. 11.4 ± 11.2%, p < 0.01) and CD38 (12.9 ± 16.7% vs. 1.7 ± 1.6%, p < 0.05), were upregulated in MAIT cells from patients with PBC compared to those from HCs (Figure 2A, Supplementary Figure 2) with the stimulation of anti-CD3 and anti-CD28 antibodies, suggesting that MAIT cells from patients with PBC were over-activated. Furthermore, MAIT cells from PBC produced significantly more IFN-γ (88.3 ± 4.2% vs. 64.2 ± 10.1%, p < 0.01), TNF-α (93.0 ± 1.1% vs. 80.1 ± 5.3%, p < 0.01), Granzyme B (89.3 ± 3.3% vs. 72.1 ± 7.0%, p < 0.01), and perforin (46.8 ± 6.6% vs. 34.8 ± 7.7%, p < 0.05), but not IL-17 (Figures 2B–E), with the stimulation of PMA and ionomycin, which indicated both pro-inflammatory and cytotoxic phenotypes. Therefore, these data suggested that MAIT cells from patients with PBC were potentially activated, produced pro-inflammatory cytokines, and might be involved in the pathological process of PBC.

CXCL12-CXCR4 PATHWAY POTENTIALLY MEDIATES ACCUMULATION OF MAIT CELLS IN THE LIVER

Given that the liver is the target organ for PBC and that it is enriched with MAIT cells, we analyzed the liver-resident MAIT cells using immunofluorescence staining. We found a higher number of CD161high TCRVα7.2+ MAIT cells in the liver (MAIT cells per mm², 899 ± 431 vs. 189 ± 76, p < 0.01, Figure 3A), including the portal area (Supplementary Figure 3) from patients with PBC than those from controls. Furthermore, the apoptosis of resting (1.5 ± 1.0% vs. 1.3 ± 1.2%, p > 0.05) MAIT cells and activated (1.3 ± 0.5% vs. 1.5 ± 0.6%, p > 0.05) MAIT cells and the proliferation potential (53.1 ± 7.9% vs. 54.5 ± 6.4%, p > 0.05) of MAIT cells from patients with PBC were comparable to those from HCs (Supplementary Figure 4), suggesting that decreased MAIT cells might result from their accumulation in the liver.

We further explored the mechanism of accumulation of MAIT cells in the aberrant liver of patients with PBC. We screened a series of chemokine receptors expressed on MAIT cells, including CXCR4, CCR10, CCR6, CXCR6, CX3CR1 (Figure 3B), CCR1, CCR3, CCR5, and CCR5 (Supplementary Figure 5). We found that MAIT cells from patients with PBC expressed higher levels of CXCR4 than those from HCs (84.8 ± 18.0% vs. 58.7 ± 11.4%, p < 0.01). Moreover, CXCR4 endogenous ligand CXCL12 was overexpressed in the liver of patients with PBC (Figure 3C). Furthermore, chemotaxis of MAIT cells was promoted by CXCL12 (10 ng/ml: 55.0 ± 8.2% vs. 42.0 ± 6.0%, p < 0.01; 30 ng/ml: 70.4 ± 6.8% vs. 52.2 ± 3.5%, p < 0.01, Figure 3D), which was attenuated by the CXCR4 antagonist, AMD3100 (42.3 ± 10.0% vs. 38.3 ± 8.8%, p < 0.05, Figure 3D). In contrast, circulating CD3+CD8+ T cells, CD3−CD56+ NK cells, and CD3+CD56+ NKT cells from patients with PBC were comparable to those from HCs (Supplementary Figure 6). Intriguingly, CD3+CD8+ T cells from patients with PBC expressed higher levels of CXCR4, but these levels were lower than those in MAIT cells (50.6 ± 20.1% vs. 84.8 ± 18.0%, p < 0.05, Supplementary Figure 7), suggesting that CXCL12 potentially less attracted CD3+CD8+ T cells. Taken together, these data supported that MAIT cells in patients with PBC might be attracted to the liver, which was mediated by the interaction between CXCL12 and CXCR4.

IL-18 Promotes MAIT Cell Activation

We examined the underlying mechanism of activation of MAIT cells from patients with PBC. We found that plasma IL-18 was higher in patients with PBC than in HCs (286.8 ± 75.7 pg/ml vs. 132.9 ± 78.1 pg/ml, p < 0.01, Figure 4A). Furthermore, MAIT cells from patients with PBC expressed higher levels of IL-18Ra than those from HCs (83.8 ± 10.2% vs. 58.3 ± 8.7%, p < 0.01, Figure 4B). MAIT cells from patients with PBC, stimulated with IL-18, significantly upregulated the production of IFN-γ (74.9 ± 6.6% vs. 54.7 ± 6.7%, p < 0.01), which was partially blocked by IL-18Ra/IL-1R5 antibody (68.6 ± 8.3% vs. 43.5 ± 4.2%, p < 0.01, Figure 4C). Thus, these data suggested that elevated circulation of IL-18 might bind to overexpressed IL-18Ra on MAIT cells and promote pro-inflammatory cytokine production in patients with PBC.

DISCUSSION

In this study, we confirmed that circulating MAIT cells were significantly decreased in patients with PBC. MAIT cells from patients with PBC potentially accumulated in the liver, which was promoted by CXCL12-mediated chemotaxis of CXCR4-expressing MAIT cells. Furthermore, MAIT cells from PBC patients were activated and produced pro-inflammatory...
Peripheral mucosal-associated invariant T cells (MAIT) cells from patients with primary biliary cholangitis (PBC) decreased significantly. (A) Representative plots of fluorescence-activated cell (FACS) (left), summary frequency (right), and absolute numbers (bottom) of peripheral CD3+CD8+CD161Tαβ7.2+ MAIT cells from patients with PBC (n = 55) and healthy controls (HCs) (n = 69). (B) Correlation of peripheral MAIT cell population with laboratory parameters in patients with PBC (n = 55). Data were expressed as mean ± SD. The value of ****p < 0.0001 by the Student’s t-test. Correlations were calculated using the Spearman’s correlation analysis.
FIGURE 2 | Activation potential of MAIT cells from patients with PBC. Peripheral blood mononuclear cells (PBMCs) were stimulated with phorbol myristate acetate (PMA) and ionomycin or anti-CD3 and anti-CD28 antibodies. Representative FACS plots (left) and summary graphs (right) of (A) CD38 (upper, PBC = 8, HC = 11) and CD69 (bottom, PBC = 24, HC = 42) expression on MAIT cells from patients with PBC and from HCs. (B) Interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). (C) Granzyme B, (D) perforin, and (E) IL-17A of MAIT cells from patients with PBC (n = 6) and from HCs (n = 6). Gray plots represent fluorescence minus one (FMO) control. The data were expressed as mean ± SD. NS, not statistically significant; *p < 0.05, **p < 0.001, and ***p < 0.0001 by Student’s t-test.
MAIT cells in patients with PBC accumulate in the liver via CXCL12–CXCR4 pathway. (A) Immunofluorescence staining of MAIT cells (arrow) in the liver of patients with PBC (n = 8) and in patients with hepatic hemangioma (Controls, n = 8). Magnification: ×400, scale bar: 50 µm. (B) Representative FACS plots (upper) and summary graphs (bottom) of CXCR4 (n = 14), CCR10, CCR6, CXCR6, and CX3CR1 on MAIT cells from patients with PBC and from HCs.
cytokines, which was mediated by elevated circulating IL-18 and IL-18Rα on MAIT cells.

The present study confirm that peripheral MAIT cells have reportedly decreased in patients with PBC (15, 16). Furthermore, peripheral MAIT cells in patients with PBC were inversely correlated with serum ALP, which is a disease activity index of PBC. Although half of the patients with PBC have hyperlipidemia, no association between circulating MAIT cells and lipid profiles was observed. However, the underlying mechanism for the decreased circulation of MAIT cells remains controversial. Jiang et al. (16) have proposed an overactivation–exhaustion model. We found that MAIT cells were indeed potentially activated. Exhaustion markers, such as PD-1, CD39, and Tim-3, were expressed by liver-resident MAIT cells, which might be induced by chronic stimuli exposure. Our data showed that circulating MAIT cells expressed lower CD39 in patients with PBC than in HCs (data not shown). However, a higher apoptotic potential in MAIT cells from patients with PBC was not observed, which did not support the hypothesis that decreased peripheral MAIT cells were induced by excessive post-activation of cell death. We noted that MAIT cells in patients with PBC mainly resided in the liver, which was consistent with the findings of Jiang et al. (16). However, Setsu et al. (15) noted that MAIT cells in patients with PBC were scarce in the liver. This discrepancy may be due to different PBC stages among studies. Similarly, excessive liver infiltration of MAIT
cells is reported in autoimmune hepatitis and non-alcoholic fatty liver (14, 20). Furthermore, T cells and aberrant chemotaxis of MAIT cells are implicated in rheumatoid arthritis and multiple sclerosis, respectively (21, 22). Therefore, the data from this study as well as from other studies supported the hypothesis that decreased circulating MAIT cells from patients with PBC were induced by excessive infiltration into the liver through aberrant chemotaxis.

Chemokines and chemokine receptors orchestrate chemotaxis. We screened T cell-expressing receptors, including CXCR4, CCR10, CCR6, CXCR6, CX3CR1, CXCIR1, CXCIR3, CXCR5, and CCR5, on MAIT cells (23). We found that CXCR4 was abnormally elevated in MAIT cells from patients with PBC. Furthermore, serum CXCL12, the CXCR4 ligand, is higher in patients with PBC (24). CXCL12 is secreted by the bile duct epithelium, especially in inflammatory conditions (25, 26). We demonstrated that CXCL12 chemotacted MAIT cells in vitro. Taken together, the inflammatory milieu of the portal area in patients with PBC might promote the bile duct epithelium to produce CXCL12, which subsequently recruits CXCR4+ MAIT cells. However, CXCR4-expressing CD3+CD8+ T cells from patients with PBC did not significantly decrease in the peripheral blood, which might attribute to lower levels in the expression of CXCR4 compared to that by MAIT cells. Thus, our study suggested that targeting the CXCL12-CXCR4 pathway might be a potential therapeutic approach to alleviate MAIT cell infiltration into the liver of patients with PBC.

Mucosal-associated invariant T cells from patients with PBC produced higher pro-inflammatory cytokines, Granzyme B, and perforin, indicating that MAIT cells were pathogenic to bile ducts. PBC is characterized by small bile duct inflammation, and perforin, indicating that MAIT cells were pathogenic to bile ducts. PBC is characterized by small bile duct inflammation, and perforin, indicating that MAIT cells were pathogenic to bile ducts. Therefore, the data from this study as well as from other studies supported the hypothesis that decreased circulating MAIT cells from patients with PBC were induced by excessive infiltration into the liver through aberrant chemotaxis.

In conclusion, MAIT cells from patients with PBC accumulated in liver via CXCL12-CXCR4-mediated chemotaxis, produced pro-inflammatory cytokines, and contributed to portal inflammation, which was potentially mediated by elevated IL-18. Targeting MAIT cells may be a therapeutic approach for PBC.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Institutional Review Board of PUMCH. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

FZ and HC designed and supervised the study. SL, LW, and CH collected samples. ZC and JS collected data. ZC performed the experiments and statistical analysis. ZC and HC drafted and revised the manuscript. FZ obtained funds. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (81771764 and 81571594), the National Key Research and Development Program of China (2016YFA0101003), the CAMS Innovation Fund for Medical Sciences (2017-I2M-3-007), and the Graduate Innovation Fund of Peking Union Medical College (2018-1002-01-03).

**ACKNOWLEDGMENTS**

We thank all patients and healthy volunteers for their participation in this study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.578548/full#supplementary-material

**REFERENCES**

1. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. *Lancet*. (2015) 386:1565–73. doi: 10.1016/S0140-6736(15)00154-3

2. Shen M, Zhang F, Zhang X. Primary biliary cirrhosis complicated with interstitial lung disease: a prospective study in 178 patients. *J Clin Gastroenterol*. (2009) 43:676–9. doi: 10.1097/MCG.0b013e318181a112

3. Shen M, Zhang F, Zhang X. Pulmonary hyperinension in primary biliary cirrhosis: a prospective study in 178 patients. *Scand J Gastroenterol*. (2009) 44:219–23. doi: 10.1080/00365520802400883

4. Bian S, Chen H, Wang L, Fei Y, Yang Y, Peng L, et al. Cardiac involvement in patients with primary biliary cholangitis: a 14-year longitudinal survey-based study. *PLoS ONE*. (2018) 13:e0194397. doi: 10.1371/journal.pone.0194397

5. Chapman RW, Lynch KD. Obeticholic acid—a new therapy in PBC NASH. *Br Med Bull*. (2020) 133:95–104. doi: 10.1093/bmb/lda006
Chen et al.

Frontiers in Immunology | www.frontiersin.org 10 March 2021 | Volume 12 | Article 578548

6. Aguilar MT, Carey EJ. Current Status of Liver Transplantation for Primary Biliary Cholangitis. Clin Liver Dis. (2018) 22:613–24. doi: 10.1016/j.cld.2018.03.011

7. McNally BB, Carey EJ. Azathioprine monotherapy is equivalent to dual therapy in maintaining remission in autoimmune hepatitis. Dig Dis Sci. (2020). doi: 10.1007/s10620-020-06347-7

8. Franciszkiewicz K, Salou M, Legoux F, Zhou Q, Cui Y, Bessoles S, et al. MHC class I-related molecule, MR1, and mucosal-associated invariant T cells. Immunol Rev. (2016) 272:120–38. doi: 10.1111/imr.12423

9. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature. (2003) 422:164–9. doi: 10.1038/nature01433

10. Dusseauex M, Martín E, Serriera N, Peguillet I, Premel V, Louis D, et al. Human MAIT cell are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood. (2011) 117:1250–9. doi: 10.1182/blood-2010-08-303339

11. Godfrey DI, Koay HF, McCluskey J, Gherardin NA. The biology and functional importance of MAIT cell. Nat Immunol. (2019) 20:1110–28. doi: 10.1038/s41590-019-0444-8

12. Bottcher K, Rombouts K, Saffioti F, Lan J, Chalasani S, Rane S, et al. Persistent reduction of mucosal-associated invariant T cells contribute to the pathogenesis of rheumatoid arthritis. Ann Rheum Dis. (2017) 76:2075–84. doi: 10.1136/annrheumdis-2016-211069

13. Li Y, Huang B, Jiang X, Chen W, Zhang J, Wei Y, et al. Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis. Expert Rev Clin Immunol. (2016) 12:661–72. doi: 10.1586/1744666X.2016.1147956

14. Yang Z, Liang Y, Lin F, Zhang Z, Luo W, Zhang Y, et al. Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis. Int Immunopharmacol. (2018) 56:285–90. doi: 10.1016/j.intimp.2018.01.046

15. Mao AW, Jiang TH, Sun XJ, Peng J. Application of chemokine receptor antagonist with stents reduces local inflammation and suppresses cancer growth. Tumour Biol. (2015) 36:8637–43. doi: 10.1007/s13277-015-3557-1

16. Ding BS, Cao Z, Li R, Nolan DJ, Guo P, Simons M, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature. (2014) 505:97–102. doi: 10.1038/nature12681

17. Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, et al. Human mucosal-associated invariant T cells contribute to antiviral inflammation immunity via IL-18-dependent activation. Proc Natl Acad Sci USA. (2016) 113:10133–8. doi: 10.1073/pnas.1607051113

18. Swidnicka-Siergiejko A, Wereszczyńska-Siemiatkowska U, Siemiatkowski A, Wasielewa-Berger J, Janica J, Mroczko B, et al. The imbalance of peripheral interleukin-18 and transforming growth factor-beta levels in patients with cirrhosis and esophageal varices. Cytokine. (2019) 115:440–5. doi: 10.1016/j.cyto.2018.10.024

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Liu, He, Sun, Wang, Chen and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.